Cannabis and Cognitive Functioning: From Acute to Residual Effects, From Randomized Controlled Trials to Prospective Designs
Authors:
Open Access
- 10 June 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 12
Abstract
In recent years, several jurisdictions have revised their regulation policy toward both medical and recreational use of cannabis. These changes have elicited concerns regarding how legalization impacts academic achievement and work performance. This review evaluates the acute and long-term (residual) association between cannabis use and cognitive functioning that underlies poor academic and work performance. Relative to other reviews, this article focuses on cross-over randomized controlled trials and prospective designs given that they allow to test the impairing effects of cannabis exposure at the within-subject level. Acute cannabis cognitive effects are discussed separately for known confounding factors such as levels of delta-9-tetrahydrocannabinol (Δ9-THC), Δ9-THC:cannabidiol ratio, previous cannabis use and, comorbidity with psychosis-spectrum disorders. The cognitive residual effects of cannabis are detailed in relation to duration of abstinence, frequency of use, comorbidity with psychosis-spectrum disorders, types of cognitive domains assessed, and age of cannabis use initiation. Moreover, considering the fact that adequate longitudinal studies can make inferences about causality between cannabis use and impaired cognitive functioning when disentangling between-subject from within-subject variation, proofs for the three main non-mutually exclusive hypotheses about this relationship will be presented: i) the cognitive vulnerability hypothesis as part of the more general common antecedent hypothesis, ii) the concurrent cannabis impairing hypothesis, and iii) the neurotoxic hypothesis of cannabis. Current research provides evidence for mild to moderate acute cannabis effects on episodic and working memory, processing speed, and executive functions. Mild residual impairing effects were also observed in these exact same cognitive domains, suggesting that adverse effects following cannabis intoxication persist at least days or weeks following cannabis abstinence. Relative to adult-onset, adolescent-onset cannabis use seems to explain the dose-response relationship and is associated with longer lasting residual effects even in mild users (<weekly). The association between cannabis and cognition is likely explained by common antecedents, such that genetic and shared environment factors predispose individuals to both cannabis use and cognitive deficits, and to a lesser degree, neurotoxic effects.Keywords
Funding Information
- Canadian Institutes of Health Research
This publication has 102 references indexed in Scilit:
- Analysis of Cannabis Seizures in NSW, Australia: Cannabis Potency and Cannabinoid ProfilePLOS ONE, 2013
- Cannabis Effects on Driving SkillsClinical Chemistry, 2013
- Persistent cannabis users show neuropsychological decline from childhood to midlifeProceedings of the National Academy of Sciences, 2012
- Effects of delta-9-tetrahydrocannabinol on evaluation of emotional imagesJournal of Psychopharmacology, 2012
- Neurophysiological functioning of occasional and heavy cannabis users during THC intoxicationPsychopharmacology, 2011
- Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-beingPsychological Medicine, 2011
- Longitudinal study of cognition among adolescent marijuana users over three weeks of abstinenceAddictive Behaviors, 2010
- The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode SampleSchizophrenia Bulletin, 2010
- Cannabinoid Modulation of Amygdala Reactivity to Social Signals of Threat in HumansJournal of Neuroscience, 2008
- Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humansPsychopharmacology, 2008